Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 17/20 | 0.57 |
| ▸ | PDCD1 | Q15116 | 15/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18979842 | 0.90 | CD274 (0.53) | CD274PDCD1ALDH1A1ALOX15TSHR | |
| SCHEMBL18979832 | 0.84 | PDCD1 (0.61) | CD274PDCD1ALDH1A1ALOX15TSHR | |
| SCHEMBL18979774 | 0.84 | CD274 (0.56) | CD274PDCD1ALDH1A1ALOX15TSHR | |
| SCHEMBL18979761 | 0.84 | PDCD1 (0.59) | CD274PDCD1ALDH1A1ALOX15TSHR | |
| SCHEMBL29516927 | 0.83 | NPC1 (0.70) | CD274PDCD1ALDH1A1ALOX15TSHR | |
| SCHEMBL18979830 | 0.82 | PDCD1 (0.68) | CD274PDCD1 | |
| SCHEMBL18979777 | 0.81 | GRM5 (0.53) | CD274PDCD1ALDH1A1ALOX15TSHR | |
| SCHEMBL18979734 | 0.81 | PDCD1 (0.64) | CD274PDCD1 | |
| SCHEMBL18979781 | 0.80 | CD274 (0.55) | CD274PDCD1ALDH1A1ALOX15TSHR | |
| SCHEMBL18979713 | 0.80 | CD274 (0.71) | CD274PDCD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2026-03-19 | — | — | US | disclosed |
| US-12516044-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| EP-3390361-B1 | N-PHENYL-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION MODULATORS | INCYTE CORP (US) | 2022-03-16 | — | — | EP | disclosed |
| EP-3390361-B1 | N-PHENYL-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION MODULATORS | INCYTE CORP (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20210363137-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-11-25 | — | — | US | disclosed |
| US-20210363137-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-11-25 | — | — | US | disclosed |
| EP-3390361-A1 | N-PHENYL-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION MODULATORS | Incyte Corporation (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20180273519-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2018-09-27 | — | — | US | disclosed |
| US-20170174671-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-06-22 | — | — | US | disclosed |
| WO-2017106634-A1 | N-PHENYL-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION MODULATORS | INCYTE CORPORATION (US) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017106634-A1 | N-PHENYL-PYRIDINE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS PD-1/PD-L1 PROTEIN/PROTEIN INTERACTION MODULATORS | INCYTE CORPORATION (US) | 2017-06-22 | — | — | WO | disclosed |
| US-20170174671-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180273519-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CD274 97/4885PDCD1 201/4885ALDH1A1 247/4885 |
| US-20210363137-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CD274 97/4885PDCD1 201/4885ALDH1A1 247/4885 |
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | MSR1, NR3C1, CCR1 | CD274 779/4885PDCD1 2387/4885ALDH1A1 868/4885 |
| US-20170174671-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CD274 97/4885PDCD1 201/4885ALDH1A1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.